Create a Free Profile
Tell us about you: what you’re living with, what you’ve tried and what you’re exploring.
Targeted Radioligand Therapy and Alpha Emitters Advanced Prostate Cancer or a Neuroendocrine Tumor
Radiation delivered from the inside, carried straight to cancer cells wherever they have spread. Find the practices that offer it and choose the ones you like.
Approved for Some Uses
Several radioligand and radiopharmaceutical therapies are FDA-approved, including for prostate cancer and neuroendocrine tumors. Newer targeted alpha therapies are investigational.
Free to join. No card required.
What Is Radioligand Therapy?
A radioligand is two things joined together: a molecule that seeks out a marker found on cancer cells, and a radioactive particle. Given by infusion, it travels through the body, attaches to the cancer cells carrying that marker and delivers radiation at very close range.
Most approved radioligands use beta-emitting particles. Alpha emitters release a heavier, shorter-range particle that may damage cancer cells more powerfully while sparing more of the tissue around them. A scan with a matching tracer is usually done first to confirm the target is there, an approach called theranostics.
Conditions It’s Used or Studied For
Metastatic Prostate Cancer
Neuroendocrine Tumors
Prostate Cancer Spread to Bone
Other Cancers (In Trials)
Only your physician can say whether it is right for you.
Before You Match
What to Know
-
A Scan Decides Eligibility
Most radioligand therapy needs a scan showing your cancer carries the target. Ask whether you have had one.
-
Approved Uses Are Specific
Approved therapies treat specific cancers, often after other treatment. Uses beyond those are offered through trials.
-
Radiation Precautions Apply
For a short time after each dose you may be asked to limit close contact with others. Ask what that means for your household.
-
Alpha Therapies Are Newer
One alpha emitter is approved for prostate cancer that has spread to bone. Most other targeted alpha therapies are investigational.
More About Radioligand Therapy
Health e Match summarized this information from the sources listed below. It is general information, not medical advice.
Who Is a Candidate?
Approved radioligand therapies treat specific cancers. Lutetium-177 PSMA therapy treats PSMA-positive metastatic prostate cancer that has progressed after hormone-based treatment. Lutetium-177 dotatate treats neuroendocrine tumors of the digestive tract and pancreas that carry somatostatin receptors. Radium-223, an alpha emitter, treats prostate cancer that has spread to bone and is causing symptoms.
Candidates usually need a scan showing the cancer carries the target, along with adequate blood counts and kidney function. Newer targeted alpha therapies are available through trials.
What to Expect
Treatment is given as an intravenous infusion or injection in a nuclear medicine or oncology department, usually in less than an hour. It is repeated in cycles, typically every four to eight weeks depending on the drug, for a set number of doses.
Some treatments include extra fluids or an amino acid infusion to help protect the kidneys. A scan with a matching tracer is usually done before treatment begins.
Recovery and Follow-Up
Most people go home the same day. For a few days after each dose you may be asked to follow radiation precautions, such as keeping distance from children and pregnant people, sleeping apart from a partner, and taking extra care with bathroom hygiene.
Blood tests between cycles check your blood counts and kidney function, and periodic scans show how the cancer is responding.
Risks and Side Effects
Common effects include tiredness, nausea and lowered blood counts. PSMA therapy can cause dry mouth because the salivary glands also take up the drug. Kidney effects are monitored over time.
Less commonly, lowered blood counts can persist, and rare blood disorders have been reported after some radioligand therapies. Radiation can affect fertility.
Cost and Insurance
Medicare and most private insurers cover approved radioligand therapies for their approved uses, usually with prior authorization. The qualifying scan also needs coverage. Ask the practice to confirm both before you start.
Choosing a Practice
Questions worth asking in your first conversation:
- Do you offer the qualifying scan (PSMA PET or somatostatin receptor imaging) on site?
- How many patients have you treated with this therapy?
- What radiation precautions will I need at home, and for how long?
- Are there targeted alpha therapy trials I might qualify for?
Alternatives to Consider
For prostate cancer, alternatives can include changes in hormone therapy, chemotherapy, PARP inhibitors for tumors with certain gene changes, and external radiation for painful bone spots. For neuroendocrine tumors, options include somatostatin analog injections, targeted oral medicines, surgery and treatments directed at the liver.
Sources
Find a Practice That Offers It
Searching for radioligand therapy usually means a long list of names and no way to tell who actually offers it. Here, you meet verified practices that treat what you listed, and you decide who to talk to.
We’ll Introduce You
We only introduce verified practices that treat what you listed.
Choose Each Other
Swipe on the ones you like. When they swipe back — it’s a match!
Free to join. No card required.
Questions
What Patients Ask
Is radioligand therapy FDA-approved?
Yes, for specific uses. Approved therapies include treatments for PSMA-positive metastatic prostate cancer and certain neuroendocrine tumors, and an alpha emitter for prostate cancer that has spread to bone. Many newer agents are investigational.
How is this different from external radiation?
External radiation is aimed at one area from outside the body. Radioligand therapy travels through the bloodstream to cancer cells carrying its target, wherever they are.
What is theranostics?
Using one molecule twice: first with a tracer to see where the cancer is on a scan, then with a therapeutic particle to treat it.
What should I list on my profile?
Your diagnosis, treatments you have had, any PSMA or similar scans, and that you are exploring radioligand therapy.
Start Matching Today
Build a free profile in minutes. List what you’re living with and that you’re exploring radioligand therapy, and meet the practices that treat it.
Free to join. No card required.
This page is general information, not medical advice, and it was last updated October 15, 2026. healthematch.com makes introductions between patients and practices in the United States. It does not provide medical care, does not enroll anyone in clinical research, and does not recommend any particular procedure or provider. Where a practice has documented a therapy’s regulatory status, it is shown exactly as documented. Are you a practice? See the radioligand therapy page for practices.